Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

Influence of Argipressin on blood loss during liver resection; a double-blinded, randomized, placebo-controlled trial (ARG-01) Ended

2024-514332-25-00 Hepatic resection due to primary malignant disease, met 4 2022-03-27
Brightline-1: A study to compare brigimadlin (BI 907828) with doxorubicin in people with a type of cancer called dedifferentiated liposarcom… Ended

2024-511361-11-00 Advanced dedifferentiated liposarcoma 10 2022-03-25
Predicting olaparib sensitivity in metastatic HER2-negative breast cancer with BRCA1, BRCA2, PALB2, RAD51C or RAD51D mutation or RAD51-negat… Ended

2024-511875-14-00 Pre and post-menopausal women and men with unresectable 4 2022-03-24
An open label, single-arm, phase 2 study of neoadjuvant sacituzumab govitecan, before radical cystectomy, for patients with muscle-invasive … Ended

2024-515301-26-00 Muscle-invasive bladder cancer 4 2022-03-23
Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination with Chemotherapy Versus Pembrolizumab Plus Chemotherapy as Fir… Ended

2023-506074-12-00 Metastatic Non-Small Cell Lung Cancer 5 2022-03-22
A research study to investigate the safety of setanaxib and helpfulness in the treatment of recurrent or metastatic squamous cell carcinoma … Ended

2023-509917-35-00 Recurrent or Metastatic Squamous Cell Carcinoma of the 4 2022-03-21
PICASSO. Prospective randomIzed clinical trial assessing the tolerance and clinical benefit of feCAl tranSplantation in patientS with melanO… Ended

2024-516100-42-00 Melanoma 4 2022-03-18
Cabozantinib in combination with Avelumab in patients refractory to standard chemotherapy with advanced neuroendocrine neoplasias G3 (NEN G3… Ended

2024-513518-37-00 Advanced neuroendocrine neoplasias G3 (NEN G3) (excludi 4 2022-03-15
A study testing increasing amounts (doses) of CC-91633 to find out what dose can be tolerated without serious side effects in patients with … Ended

2023-503869-34-00 Acute myeloid leukemia or myelodysplastic syndrome of h 1 2022-03-15
Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants with Relapsed or Refractory Multiple Myeloma (DREAM… Ended

2023-508213-16-00 Multiple Myeloma 4 2022-03-15
DESTINY-Breast08 will investigate the safety, tolerability, PK and preliminary anti-tumour activity of T-DXd in combination with other thera… Ended

2023-505690-33-00 Metastatic Breast Cancer 3 2022-03-11
Impact of neoadjuvant immunotherapy in early stage breast cancer before standard therapy (BIS-Program) Ended

2024-512826-26-00 Newly diagnosed, non-metastatic early-stage triple-nega 4 2022-03-07
A phase 2 trial to study safety and efficacy of Capivasertib in patients with blood cancer where disease or cancer cell grows after a period… Ended

2024-516386-36-00 Relapsed or Refractory B-cell Non-Hodgkin Lymphoma 4 2022-03-04
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination with Glofitamab in Participants wit… Ended

2023-506699-29-00 Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (r/r 3 2022-03-03
A study evaluating the safety and efficacy of anti-CD19 CAR T in subjects with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Ended

2022-501686-47-00 relapsed/refractory chronic lymphocytic leukemia relaps 7 2022-02-28
Inducta Ended

2023-509837-37-00 Patients with locally advanced T4 high risk prostate ca 4 2022-02-25
A Phase 1/2, Open-label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Fadraciclib (CYC065), an Oral CDK2/9… Ended

2024-516289-12-00 Endometrial cancer, Ovarian cancer, Biliary tract cance 9 2022-02-24
A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Clinical Activity of RO7276389 Alone and in Combination with Cobimetinib in Pa… Ended

2023-506310-43-00 BRAF-V600 Mutation-Positive Advanced Solid Tumor or BRA 1 2022-02-15
Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumours Ended

2024-511071-16-00 Solid Tumours 3 2022-02-10
A First-in-Human Study to Evaluate the Safety and Anti-cancer Activity of the product FS120, which is an Antibody medication, to be administ… Ended

2024-514777-22-00 Advanced Malignancies 1 2022-02-07
A Research Study, where the participant and healthcare providers are aware of the treatment being given, to evaluate safety and effectivenes… Ended

2022-501243-33-00 Diffuse Large B Cell Lymphoma (a type of non-Hodgkin’s 4 2022-02-03
Targeting ATR in soft-tissue sarcomas: a randomized phase II study Ended

2023-509499-41-00 Adult patients with locally advanced/unresectable and/o 4 2022-02-03
Study Comparing Bemarituzumab plus Chemotherapy with Placebo and Chemotherapy in Previously Untreated Advanced Gastric or Gastroesophageal J… Ended

2023-505457-40-00 Previously Untreated Advanced Gastric or Gastroesophage 5 2022-02-02
GRAPPA Ended

2023-510441-24-00 Graft Vs Host Disease Peripheral Blood Stem Cell Transp 5 2022-01-28